Sheng-Yu Lee1, Liang-Jen Wang2, Cheng-Ho Chang3, Chih-Ching Wu4, Hsing-Ling Chen5, Shih-Hsien Lin6, Chin-Liang Chu3, Ti Lu3, Ru-Band Lu7. 1. Department of Psychiatry, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan; Department of Psychiatry, College of Medicine, Graduate Institute of Medicine, School of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; Department of Psychiatry, College of Medicine, National Cheng Kung University, Tainan, Taiwan. Electronic address: shirleylee.ncku@gmail.com. 2. Department of Child and Adolescent Psychiatry, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan. 3. Department of Psychiatry, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan. 4. Department of Medical Biotechnology and Laboratory Science, College of Medicine, Chang Gung University, Taoyuan, Taiwan; Department of Otolaryngology-Head & Neck Surgery, Chang Gung Memorial Hospital, Linkou, Taiwan. 5. Department of Nuclear Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan. 6. Department of Psychiatry, College of Medicine, National Cheng Kung University, Tainan, Taiwan. 7. Department of Psychiatry, College of Medicine, National Cheng Kung University, Tainan, Taiwan; Institute of Behavioral Medicine Sciences, College of Medicine and Hospital, National Cheng Kung University, Tainan, Taiwan; Center for Neuropsychiatric Research, National Health Research Institutes, Miaoli, Taiwan.
Abstract
OBJECTIVES: Dysregulation of the neuroendocrine system including dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulfate (DHEA-S), and pregnenolone may play a role in the pathophysiology of bipolar II disorder (BP-II). The aims of the current study are to determine (a) the differences in DHEA, DHEA-S and pregnenolone in patients with BP-II and controls; and (b) the correlation of levels of the above hormones, cognitive function, and clinical symptoms. METHODS: Patients diagnosed with BP-II and healthy controls were recruited from psychiatric department. Blood samples were collected to measure the levels of DHEA, DHEA-S and pregnenolone in all participants, followed by assessment of cognitive function using the Brief Assessment of Cognition in Affective Disorders (BACA). RESULTS: A total of 32 patients BP-II and 30 healthy control subjects were recruited. The BP-II group was found with significantly elder age, fewer years of education, and lower BACA composite scores compared to the healthy controls. The level of DHEA-S was significantly associated with performance in BACA when controlling for age, gender, years of education and having BP-II (P=0.018). The DHEA-S level was significantly correlated with mania score (r=-0.498, P=0.010). CONCLUSION: Our findings support that serum level of DHEA-S may be a biomarker representing clinical manic symptoms and cognitive performance.
OBJECTIVES: Dysregulation of the neuroendocrine system including dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulfate (DHEA-S), and pregnenolone may play a role in the pathophysiology of bipolar II disorder (BP-II). The aims of the current study are to determine (a) the differences in DHEA, DHEA-S and pregnenolone in patients with BP-II and controls; and (b) the correlation of levels of the above hormones, cognitive function, and clinical symptoms. METHODS:Patients diagnosed with BP-II and healthy controls were recruited from psychiatric department. Blood samples were collected to measure the levels of DHEA, DHEA-S and pregnenolone in all participants, followed by assessment of cognitive function using the Brief Assessment of Cognition in Affective Disorders (BACA). RESULTS: A total of 32 patientsBP-II and 30 healthy control subjects were recruited. The BP-II group was found with significantly elder age, fewer years of education, and lower BACA composite scores compared to the healthy controls. The level of DHEA-S was significantly associated with performance in BACA when controlling for age, gender, years of education and having BP-II (P=0.018). The DHEA-S level was significantly correlated with mania score (r=-0.498, P=0.010). CONCLUSION: Our findings support that serum level of DHEA-S may be a biomarker representing clinical manic symptoms and cognitive performance.
Authors: V Matulevicius; V Urbanavicius; S Lukosevicius; I Banisauskaite; G Donielaite; A Galkine Journal: Acta Endocrinol (Buchar) Date: 2021 Apr-Jun Impact factor: 0.877
Authors: Samuel J A Gubb; Lucija Brcic; Jack F G Underwood; Kimberley M Kendall; Xavier Caseras; George Kirov; William Davies Journal: Hum Mol Genet Date: 2020-10-10 Impact factor: 6.150